低氧诱导因子稳定作为慢性肾脏病相关贫血新兴治疗:美国国家肾脏基金会科学研讨会报告
美国国家肾脏基金会于2019年3月召开国际跨学科研讨会,讨论低氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHIs)治疗慢性肾脏病(CKD)贫血的潜在作用。与会专家回顾了当前贫血治疗未满足需求、HIF生物学、HIF-PHIs药理学及CKD患者(透析与非透析)的2期临床试验结果,并纳入写作时已发表的3期试验。研讨会就长期安全性、潜在获益及实施考虑提出多项建议。
要点
- HIF-PHIs是治疗CKD贫血的新一类口服药物,研讨会评估其生物学与早期临床试验。
- 现有贫血治疗存在未满足需求,HIF-PHIs可能提供替代途径。
- 研讨会建议进一步研究长期安全性、潜在获益及患者与提供者教育等实施问题。
核心结论
- HIF-PHIs作为CKD相关贫血的新兴治疗,需进一步评估长期安全性、潜在获益及实施考虑。
研究设计与样本
- 美国国家肾脏基金会于2019年3月召开国际跨学科科学研讨会,参与者包括生理学、生物化学、结构化学、转化医学及贫血临床管理专家。
- 研讨会回顾了当前贫血治疗未满足需求、HIF生物学、HIF-PHIs药理学及CKD患者(透析与非透析)的2期临床试验结果,并纳入写作时已发表的3期试验。
主要发现
- 研讨会总结了HIF-PHIs在CKD贫血患者中的2期临床试验结果,涵盖透析和非透析患者。
- 写作时已发表的HIF-PHIs关键3期临床试验结果也被纳入报告。
临床怎么用
- 研讨会提出的建议包括对HIF-PHIs长期安全性、潜在获益及实施考虑(如患者与提供者教育)进行进一步审查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The National Kidney Foundation convened an interdisciplinary international workshop in March 2019 to discuss the potential role of a new class of agents for the treatment of anemia in patients with chronic kidney disease (CKD): the hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). International experts with expertise in physiology, biochemistry, structural chemistry, translational medicine, and clinical management of anemia participated. Participants reviewed the unmet needs of current anemia treatment, the biology of hypoxia-inducible factor, the pharmacology of prolyl hydroxylase inhibitors, and the results of phase 2 clinical trials of HIF-PHIs among patients with CKD, both those treated by dialysis and those not receiving kidney replacement therapy. The results of key phase 3 clinical trials of HIF-PHIs available as of the time of writing are also included in this report, although they appeared after the workshop was completed. Participants in the workshop developed a number of recommendations for further examination of HIF-PHIs, which are summarized in this report and include long-term safety issues, potential benefits, and practical considerations for implementation including patient and provider education.
引用
- Wish JB, Eckardt KU, Kovesdy CP, et al. Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation. Am J Kidney Dis. 2021. PMID: 34332007. doi:10.1053/j.ajkd.2021.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。